DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2021-03-11

Last Posted Date: 2024-12-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 825

Registration Number: NCT04794010

Locations: 🇩🇪
Local Institution - 0001, Leipzig, Germany

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Deucravacitinib
Other: Placebo matching deucravacitinib

First Posted Date: 2021-02-26

Last Posted Date: 2025-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 153

Registration Number: NCT04772079

Locations: 🇵🇱
Local Institution - 0011, Krakow, Poland
🇧🇷
Centro de Pesquisas da Clínica IBIS, Salvador, Bahia, Brazil
🇦🇷
Instituto de Neumonologia Y Dermatologia, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

and more 60 locations

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

Phase 2

Completed

Conditions: Heart Failure With Preserved Ejection Fraction

Interventions: Drug: mavacamten

First Posted Date: 2021-02-23

Last Posted Date: 2025-03-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT04766892

Locations: 🇺🇸
Local Institution - 0014, Miami, Florida, United States
🇺🇸
Local Institution - 0011, Tucson, Arizona, United States
🇺🇸
Local Institution - 0005, Los Angeles, California, United States

and more 18 locations

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Phase 1

Terminated

Conditions: Nonalcoholic Fatty Liver Disease

Interventions: Other: Placebo matching BMS-963272
Drug: BMS-963272

First Posted Date: 2021-02-23

Last Posted Date: 2022-06-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT04766476

Locations: 🇺🇸
Arizona Liver Health - Tucson, Tucson, Arizona, United States
🇺🇸
Pinnacle Clinical Research - Austin, Austin, Texas, United States
🇺🇸
Local Institution, San Antonio, Texas, United States

and more 4 locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986308
Drug: Furosemide
Other: Placebo (for BMS-986308)

First Posted Date: 2021-02-21

Last Posted Date: 2022-04-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT04763226

Locations: 🇺🇸
Local Institution - 0001, Lenexa, Kansas, United States

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Biological: BMS-986326
Other: Placebo matching BMS-986326
Biological: Multiple Ascending Dose SC
Other: Multiple Ascending Dose Placebo

First Posted Date: 2021-02-03

Last Posted Date: 2024-05-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 88

Registration Number: NCT04736134

Locations: 🇩🇪
Local Institution - 0001, Berlin, Germany

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Phase 1

Terminated

Conditions: High-grade Glioma
Miscellaneous Brain Tumors
Miscellaneous Solid Tumors
Medulloblastoma
Ependymoma
Ewing Sarcoma
Leukemia and Lymphoma
Neuroblastoma
Relapsed, Refractory Malignant Neoplasms
Rhabdomyosarcoma

Interventions: Biological: Nivolumab
Biological: NKTR-214

First Posted Date: 2021-01-29

Last Posted Date: 2023-03-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT04730349

Locations: 🇦🇺
Local Institution - 0003, Perth, Western Australia, Australia
🇫🇷
Local Institution - 0015, Paris, France
🇪🇸
Local Institution - 0059, Sevilla, Spain

and more 15 locations

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Extensive-stage Small Cell Lung Cancer

Interventions: Biological: BMS-986012
Drug: Carboplatin
Drug: Etoposide
Biological: Nivolumab

First Posted Date: 2021-01-11

Last Posted Date: 2024-07-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 120

Registration Number: NCT04702880

Locations: 🇺🇸
Local Institution - 0060, Cincinnati, Ohio, United States
🇺🇸
Local Institution - 0002, Durham, North Carolina, United States
🇦🇺
Local Institution - 0004, Murdoch, Western Australia, Australia

and more 35 locations

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Phase 1

Terminated

Conditions: Healthy Participants
Primary Sjögren's Syndrome

Interventions: Biological: BMS-986325
Other: Placebo for BMS-986325

First Posted Date: 2020-12-24

Last Posted Date: 2023-08-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 118

Registration Number: NCT04684654

Locations: 🇺🇸
Medvin Clinical Research - Metyas, Covina, California, United States
🇩🇪
Local Institution - 0001, Berlin, Germany

Effect of BMS-986165 on the Blood Levels of Metformin

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: Metformin

First Posted Date: 2020-12-17

Last Posted Date: 2021-11-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT04671953

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy